Mg-containing Biodegradable Polymer Bone Repair Material

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-01

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The patients was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting, the clinical role for bone will be assessed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biodegradable Magnesium Bone Plate and Screw Fixation in Jaw Surgery

NCT06536660

Orthognathic Surgical Procedures

NOT_YET_RECRUITING NA

The Clinical Study of 3D-printed Magnesium Alloy Prosthesis With Controllable Degradation Rate in the Repair of Periarticular Bone Defects

NCT06349629

Degradation of Magnesium Alloy Prosthesis and New Bone Regeneration

RECRUITING NA

Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects

NCT07066228

Defective Composite Restorations Bone Cysts Bone Defect +1 more

RECRUITING NA

The Clinical Therapeutic Effects and Safety of Tissue-engineered Bone

NCT02748343

Bone Defect Bone Nonunion

UNKNOWN PHASE1/PHASE2

Clinical Trial on the Safety and Efficacy of Magnesium Doped Calcium Silicate 3d Alveolar Bone Repair Unit for Periodontal Bone Defects

NCT05743452

Alveolar Bone Loss

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The subjects were randomly divided into experimental group and control group. The experimental group was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd., while the control group was treated with bone graft β- Tricalcium phosphate bioceramics were used for bone transplantation. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting. It is estimated that 176 cases will be recruited in total, and 135 cases have been recruited since April 2021. This product can be degraded and absorbed in vivo, and it can promote the formation of new bone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Deformity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

magnesium containing biodegradable polymer bone repair material

The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.

Group Type PLACEBO_COMPARATOR

Device

Intervention Type DEVICE

The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.

β- Tricalcium phosphate bioceramics

Control group application β- Tricalcium phosphate bioceramics for treatment.

Group Type PLACEBO_COMPARATOR

Device

Intervention Type DEVICE

The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Device

The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years old and ≤ 75 years old, regardless of gender;
2. Bone defect exists in one of the following anatomical positions, and bone grafting is required:

Upper limb bones: humerus, ulna, radius, metacarpus, carpus, phalanges;

Lower limb bones: femur, tibia, fibula, calcaneus, navicular bone, wedge bone, cuboid bone, metatarsal bone, talus and phalanges;
3. The maximum diameter of the expected or actual three-dimensional bone defect is ≥ 0.5cm and ≤ 6cm, and the defect is only one;
4. The bone defect site is expected to be fixed with non-degradable internal fixation system during operation;
5. Subjects or their legal representatives can understand the purpose of the study and show sufficient compliance with the study protocol and sign the informed consent form.

Exclusion Criteria

1. The blood glucose control is unstable and cannot meet the operation conditions;
2. Severe coagulation dysfunction (PT or APTT ≥ 2 times the upper limit of normal value);
3. History of arterial thrombosis attack (such as stroke, angina pectoris, acute myocardial infarction, etc.) or NYHA grade ≥ III within 3 months before enrollment;
4. Oral or injection of sedative and hypnotic drugs or non-steroidal anti-inflammatory drugs (except aspirin) every week within 3 months before enrollment;
5. He had received chemotherapy drugs or radiotherapy within 3 months before admission;
6. Cumulative oral or injection of corticosteroids or various growth factors for ≥ 14 days within 1 month before enrollment;
7. Suffering from systemic infection or uncontrollable local infection, serious soft tissue injury at the proposed operation site, serious vascular or nerve injury, malignant tumor, confirmed severe malnutrition or other important organ failure;
8. The limb to be operated on has osteofascial compartment syndrome;
9. Structural bone grafting is required;
10. Pregnant or lactating women;
11. Participate in clinical trials of other drugs or medical devices within one month before enrollment;
12. For the benefit of the subject, the researcher believes that it should not participate in other situations of this clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No